Prognostic value of sequencing of radiotherapy and chemotherapy following breast-conserving surgery for patients with breast cancer

• Published in: Zhōnghuá zhŏngliú zázhì Vol. 39; no. 4; pp. 308 - 314
• Main Authors: Zhong, Q Z, Wang, Z, Tang, Y, Rong, Q L, Wang, S L, Jin, J, Wang, W H, Liu, Y P, Song, Y W, Fang, H, Chen, B, Qi, S N, Li, N, Zhang, J H, Li, Y X
• Format: Journal Article
• Language: Chinese
• Published: China 23.04.2017
• Subjects: Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Chemotherapy, Adjuvant - methods; Chemotherapy, Adjuvant - mortality; Chemotherapy, Adjuvant - utilization; Disease-Free Survival; Female; Humans; Mastectomy, Segmental; Prognosis; Radiotherapy, Adjuvant - methods; Radiotherapy, Adjuvant - mortality; Radiotherapy, Adjuvant - utilization; Retrospective Studies; Survival Rate; Time Factors; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - mortality; Triple Negative Breast Neoplasms - radiotherapy; Triple Negative Breast Neoplasms - surgery
• ISSN: 0253-3766
• DOI: 10.3760/cma.j.issn.0253-3766.2017.04.015

To evaluate the prognostic value of sequencing of adjuvant radiotherapy and chemotherapy following breast-conserving surgery for patients with breast cancer. A total of 1 154 patients withT1-2N0-3M0 breast cancer retrospectively reviewed. All patients received sequential radiotherapy and chemotherapy following breast-conserving surgery. Among them, 603 patients received radiotherapy first and 551 patients received chemotherapy first. Log-rank tests were used to determine significance of disease-free survival (DFS) and overall survival (OS) rates in the Kaplan-Meier curve. The 5-year DFS and OS rates for all patients were 93.0% and 97.8%. The 5-year OS rate was 98.6% in the radiotherapy first group and 96.4% in the chemotherapy first group ( =0.191), and the corresponding DFS rate was 92.7% and 93.2% ( =0.430), respectively. Among the patients with Luminal A subtype, the 5-year OS rate was 99.6% in the radiotherapy first group and 97.8% in the chemotherapy first group ( =0.789). Among the patients with Luminal